874650-39-2

Basic information

• Product Name: 1,3-Cyclopentanediol, mono(4-methylbenzenesulfonate)
• CAS NO: 874650-39-2
• Molecular Formula: C12H16O4S
• Molecular Weight: 256.323
• Mol File: 874650-39-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1,3-Cyclopentanediol, mono(4-methylbenzenesulfonate)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Cyclopentanediol, mono(4-methylbenzenesulfonate)(874650-39-2)
• EPA Substance Registry System: 1,3-Cyclopentanediol, mono(4-methylbenzenesulfonate)(874650-39-2)

Safety Data

• Hazardous Substances Data: 874650-39-2(Hazardous Substances Data)

Upstream product

• 16326-97-9 1,3-dihydroxycyclopentane 
• 98-59-9 p-toluenesulfonyl chloride 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.